Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Understanding intercalation compounds for sodium-ion batteries and beyond.

Kaufman JL, Vinckevičiūtė J, Krishna Kolli S, Gabriel Goiri J, Van der Ven A.

Philos Trans A Math Phys Eng Sci. 2019 Aug 26;377(2152):20190020. doi: 10.1098/rsta.2019.0020. Epub 2019 Jul 8.

PMID:
31280717
2.

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.

Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J.

Blood. 2019 Aug 22;134(8):668-677. doi: 10.1182/blood.2019000667. Epub 2019 Jul 3.

PMID:
31270103
3.

Registering a CD38 antibody upfront for multiple myeloma.

Hofmeister CC, Nooka A, Kaufman JL, Lonial S.

Lancet. 2019 Jul 6;394(10192):3-4. doi: 10.1016/S0140-6736(19)31250-4. Epub 2019 Jun 3. No abstract available.

PMID:
31171418
4.

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.

Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, Boise LH, Lonial S.

Cancer. 2019 Sep 1;125(17):2991-3000. doi: 10.1002/cncr.32178. Epub 2019 May 15.

PMID:
31090928
5.

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, Hofmeister CC, Kaufman JL, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM, Boise LH.

Nat Commun. 2019 Apr 23;10(1):1911. doi: 10.1038/s41467-019-09555-6.

6.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV.

JCI Insight. 2019 Apr 23;5. pii: 127807. doi: 10.1172/jci.insight.127807.

7.

Daratumumab in multiple myeloma.

Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S.

Cancer. 2019 Jul 15;125(14):2364-2382. doi: 10.1002/cncr.32065. Epub 2019 Apr 5. Review.

PMID:
30951198
8.

Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies.

Harvey RD, Zhang C, Lonial S, Kaufman JL, Chen Z.

Cancer. 2019 Mar 28. doi: 10.1002/cncr.32080. [Epub ahead of print] No abstract available.

PMID:
30919409
9.

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG.

Leukemia. 2019 Jul;33(7):1736-1746. doi: 10.1038/s41375-019-0384-1. Epub 2019 Jan 29.

PMID:
30696949
10.

Invited commentary.

Kaufman JL.

J Vasc Surg. 2019 Feb;69(2):452-453. doi: 10.1016/j.jvs.2018.05.201. No abstract available.

PMID:
30683194
11.

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.

Matulis SM, Gupta VA, Neri P, Bahlis NJ, Maciag P, Leverson JD, Heffner LT Jr, Lonial S, Nooka AK, Kaufman JL, Boise LH.

Leukemia. 2019 May;33(5):1291-1296. doi: 10.1038/s41375-018-0374-8. Epub 2019 Jan 24. No abstract available.

PMID:
30679802
12.

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S.

Blood Cancer J. 2019 Jan 4;9(1):3. doi: 10.1038/s41408-018-0154-8.

13.

Safety and survival outcomes for bloodless transplantation in patients with myeloma.

Joseph NS, Kaufman JL, Boise LH, Valla K, Almaula DK, Obidike CO, Langston AA, Waller EK, Khoury HJ, Flowers CR, Graiser M, Heffner LT, Lonial S, Nooka AK.

Cancer. 2019 Jan 15;125(2):185-193. doi: 10.1002/cncr.31677. Epub 2018 Nov 27. Review.

PMID:
30480777
14.

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.

Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, Boise LH, Dhodapkar MV, Gleason C, Nooka AK, Lonial S.

Cancer. 2019 Feb 1;125(3):416-423. doi: 10.1002/cncr.31718. Epub 2018 Oct 17.

PMID:
30332496
15.

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.

Chehab S, Zhang C, Panjic EH, Chen Z, Kaufman JL, Lonial S, Nooka A, Harvey RD.

Cancer. 2018 Nov 15;124(22):4358-4365. doi: 10.1002/cncr.31746. Epub 2018 Oct 10.

PMID:
30303526
16.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ.

Haematologica. 2018 Dec;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. Epub 2018 Sep 20.

17.

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.

Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, Richardson PG, Raje NS.

JAMA Oncol. 2018 Dec 1;4(12):e183267. doi: 10.1001/jamaoncol.2018.3267. Epub 2018 Dec 13.

18.

Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.

Chang A, Nasti TH, Khan MK, Parashar S, Kaufman JL, Boise LH, Lonial S, Ahmed R, Nooka AK.

J Oncol Pract. 2018 Sep;14(9):561-564. doi: 10.1200/JOP.18.00208. Epub 2018 Jul 13. No abstract available.

PMID:
30004825
19.

Novel Approaches for the Management of AL Amyloidosis.

Joseph NS, Kaufman JL.

Curr Hematol Malig Rep. 2018 Jun;13(3):212-219. doi: 10.1007/s11899-018-0450-1. Review.

PMID:
29951831
20.

A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.

Dimopoulos MA, Kaufman JL, White D, Cook G, Rizzo M, Xu Y, Fahrbach K, Gaudig M, Slavcev M, Dearden L, Lam A.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):163-173.e6. doi: 10.1016/j.clml.2017.12.011. Epub 2018 Jan 5.

21.

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.

Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, Kaufman JL, McCarty JM, Vargo R, Cheverton PD, Struijs M, Bolwell B, DiPersio JF.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1187-1195. doi: 10.1016/j.bbmt.2018.01.039. Epub 2018 Feb 2.

22.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C.

Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.

23.

A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.

Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial S.

Cancer. 2017 Dec 1;123(23):4617-4630. doi: 10.1002/cncr.30892. Epub 2017 Aug 17.

24.

High-risk Multiple Myeloma: Definition and Management.

Joseph NS, Gentili S, Kaufman JL, Lonial S, Nooka AK.

Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S80-S87. doi: 10.1016/j.clml.2017.02.018. Review.

PMID:
28760306
25.

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S.

Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.

26.

Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S, Boise LH.

Blood. 2017 Apr 6;129(14):1969-1979. doi: 10.1182/blood-2016-10-745059. Epub 2017 Feb 1.

27.

Insights Into the Appropriate Use of New Antimyeloma Therapies.

Kaufman JL, Lonial S.

Oncology (Williston Park). 2017 Jan 15;31(1):64, 66. No abstract available.

28.

The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists.

Tiao J, Feng R, Bird S, Choi JK, Dunham J, George M, Gonzalez-Rivera TC, Kaufman JL, Khan N, Luo JJ, Micheletti R, Payne AS, Price R, Quinn C, Rubin AI, Sreih AG, Thomas P, Okawa J, Werth VP.

Br J Dermatol. 2017 Feb;176(2):423-430. doi: 10.1111/bjd.15140. Epub 2016 Dec 22.

29.

Who Is Really the Communicator of Adverse Outcomes-And When?

Kaufman JL.

Anesthesiology. 2017 Jan;126(1):194. No abstract available.

PMID:
27977456
30.

Treatment of Malignant Superior Vena Cava Syndrome Using a Bifurcated Aortic Endograft.

Kahn SL, Kravetz AJ, Norris MA, Kaufman JL.

J Vasc Interv Radiol. 2016 Nov;27(11):1708-1710. doi: 10.1016/j.jvir.2016.07.003. No abstract available.

PMID:
27926389
31.

A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.

Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JL.

Cancer. 2016 Nov 15;122(21):3327-3335. doi: 10.1002/cncr.30174. Epub 2016 Jul 19.

32.

Massive Hemorrhage From Multiple Hepatic Artery Aneurysms.

Kahn SL, McClain J, Kaufman JL.

Vasc Endovascular Surg. 2016 Oct;50(7):507-510. Epub 2016 Sep 14.

PMID:
27630223
33.

Extravascular Revascularization of a Chronic Total Occlusion Using the Dual Bull's-Eye Technique.

Kahn SL, Kaufman JL.

J Endovasc Ther. 2016 Dec;23(6):903-906. Epub 2016 Aug 29.

PMID:
27573020
34.

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.

DeFilipp Z, Rosand CB, Goldstein DA, Master VA, Carthon BC, Harris WB, Kucuk O, Al-Kadhimi Z, Cohen JB, Flowers CR, Lechowicz MJ, Nooka AK, Kaufman JL, Langston AA, Chen Z, Arora J, Waller EK.

Bone Marrow Transplant. 2017 Jan;52(1):132-134. doi: 10.1038/bmt.2016.189. Epub 2016 Jul 18. No abstract available.

PMID:
27427922
35.

Decreasing the Hours That Anesthesiologists and Nurse Anesthetists Work Late.

Kaufman JL.

Anesth Analg. 2016 Sep;123(3):791. doi: 10.1213/ANE.0000000000001360. No abstract available.

PMID:
27331775
36.

Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.

Ponder KG, Matulis SM, Hitosugi S, Gupta VA, Sharp C, Burrows F, Nooka AK, Kaufman JL, Lonial S, Boise LH.

Cancer Biol Ther. 2016 Jul 2;17(7):769-77. doi: 10.1080/15384047.2016.1192086.

37.

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

Siegel DS, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):329-334.e1. doi: 10.1016/j.clml.2016.02.042. Epub 2016 Mar 4.

PMID:
27025160
38.

Computed tomography of the aorta with heart.

Kaufman JL.

J Vasc Surg. 2016 Apr;63(4):1090. doi: 10.1016/j.jvs.2014.10.098. No abstract available.

39.

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, Laubach JP, Chauhan D, Jakubowiak AJ, Reich S, Trikha M, Anderson KC.

Blood. 2016 Jun 2;127(22):2693-700. doi: 10.1182/blood-2015-12-686378. Epub 2016 Mar 23.

40.

Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.

Berdeja J, Jagannath S, Zonder J, Badros A, Kaufman JL, Manges R, Gupta M, Tendolkar A, Lynch M, Bleickardt E, Paliwal P, Vij R.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):129-38. doi: 10.1016/j.clml.2015.12.007. Epub 2015 Dec 21.

41.

Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.

Matulis SM, Gupta VA, Nooka AK, Hollen HV, Kaufman JL, Lonial S, Boise LH.

Leukemia. 2016 May;30(5):1086-93. doi: 10.1038/leu.2015.350. Epub 2015 Dec 28.

42.

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG.

Blood. 2015 Nov 12;126(20):2284-90. doi: 10.1182/blood-2015-05-643320. Epub 2015 Sep 17.

43.

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.

Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, Bumpers N, Colbert A, Hutchison-Rzepka A, Nastoupil LJ, Heffner LT, Langston AA, Lechowicz MJ, Lonial S, Flowers CR.

Br J Haematol. 2015 Nov;171(4):539-46. doi: 10.1111/bjh.13637. Epub 2015 Aug 7.

44.

Surgical drainage of a small tissue volume with butterfly infusion and vacuum phlebotomy tube sets.

Kaufman JL.

J Am Coll Surg. 2015 Jun;220(6):e79-80. doi: 10.1016/j.jamcollsurg.2015.02.017. Epub 2015 Feb 28. No abstract available.

PMID:
25872687
45.

The concept of risk in comparative effectiveness research.

Kaufman JL.

N Engl J Med. 2015 Feb 26;372(9):884. doi: 10.1056/NEJMc1415933. No abstract available.

PMID:
25714179
46.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG.

Lancet Oncol. 2014 Dec;15(13):1503-1512. doi: 10.1016/S1470-2045(14)71125-8. Epub 2014 Nov 14. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
25456369
47.

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.

Barbee MS, Nooka A, Kaufman JL, Kim S, Chen Z, Heffner LT Jr, Lonial S, Harvey RD.

Cancer. 2015 Mar 15;121(6):853-62. doi: 10.1002/cncr.29136. Epub 2014 Nov 6.

48.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Bladé J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG.

Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25242045
49.

The Tao of myeloma.

Boise LH, Kaufman JL, Bahlis NJ, Lonial S, Lee KP.

Blood. 2014 Sep 18;124(12):1873-9. Review.

50.

Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema.

Shams SR, Goldstein DA, Kaufman JL, MacKelfresh J, Flowers CR, Langston AA.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e213-5. doi: 10.1016/j.clml.2014.06.018. Epub 2014 Jun 21. No abstract available.

PMID:
25065780

Supplemental Content

Loading ...
Support Center